Patents Represented by Attorney, Agent or Law Firm Bruce A. Pokras
  • Patent number: 5747066
    Abstract: Mixed micelles for the aqueous solubilization of active substances which are difficultly soluble or insoluble in water with improved storage properties consist of a phosphatide having saturated, branched fatty acid residues and a bile acid salt or dihexanoyllecithin.
    Type: Grant
    Filed: March 7, 1996
    Date of Patent: May 5, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Folker Pittrof, Hans Steffen
  • Patent number: 5702579
    Abstract: A process for the preparation of ascorbic acid starting from an ascorbate is characterized in that an ascorbate, e.g. sodium ascorbate, dissolved in water is decomposed under the influence of an electric field by means of ion-selective membranes into ascorbate ions and cations and the latter are separated spatially from one another and then, as a result of simultaneous generation of protons and hydroxide ions, the ascorbic acid is prepared from the liberated ascorbate ions and protons and, spatially separated therefrom, the corresponding hydroxide, e.g. sodium hydroxide, is also prepared from the cations and hydroxide ions.
    Type: Grant
    Filed: December 13, 1996
    Date of Patent: December 30, 1997
    Assignee: Roche Vitamins Inc.
    Inventor: Joachim Veits
  • Patent number: 5700836
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is a residue of the formula ##STR2## and R.sup.2 -R.sup.10 have the significance given in the specification can be used as pharmaceuticals, particularly for the repair of photodamaged skin, other dermatological conditions, and oncological indications.
    Type: Grant
    Filed: October 21, 1996
    Date of Patent: December 23, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Klaus, Peter Mohr
  • Patent number: 5693755
    Abstract: A synthetic gene which codes for at least one epitope from the immunodominant conserved region of HTLV-I env. gp 21 as well as hybrid genes utilizing the synthetic gene in conjunction with other epitopes from HTLV-Ienv.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: December 2, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Deborah Anne Buonagurio, Mathew Longiaru
  • Patent number: 5688946
    Abstract: The compounds of the formula ##STR1## in the form of optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates as well as pharmaceutically usable salts thereof inhibit the activity of the natural enzyme renin and can accordingly be used in the form of pharmaceutical preparations in the control or prevention of high blood pressure and cardiac insufficiency.
    Type: Grant
    Filed: July 19, 1994
    Date of Patent: November 18, 1997
    Assignee: Hoffmann La Roche Inc.
    Inventors: Quirico Branca, Werner Neidhart, Henri Ramuz, Heinz Stadler, Wolfgang Wostl
  • Patent number: 5681977
    Abstract: Novel processes and intermediates useful for the manufacture of the Wittig ester salts are disclosed. The Wittig ester salts are known as important C.sub.5 building blocks for the manufacture of various polyenecarboxylic acid esters in the field of carotenoid chemistry.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: October 28, 1997
    Assignee: Roche Vitamins Inc.
    Inventors: Bruno Burdet, August Ruttimann, Jean-Marie Santer, Theodor Siegfried
  • Patent number: 5677419
    Abstract: Analogs of porcine Vasoactive Intestinal Peptide are disclosed. The analogs have been cyclized by the covalent attachment, via an amide bond, of the side-chain carboxy terminus of one amino acid in the peptide chain to the side-chain amino terminus of another amino acid in the peptide chain. The claimed compounds are useful for the treatment of asthma.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: October 14, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David Robert Bolin, Margaret O'Donnell
  • Patent number: 5672513
    Abstract: The present invention provides recombinant CEA glycoproteins and methods for their production. These recombinant CEA glycoproteins s lack the C-terminal 26 amino acids which are present in natural CEA and are characterized in that they are free from cross-reactive CEA-like antigens, antigenically indistingiushable from the soluble form of CEA shed from tumor cells, and devoid of the ethanolamine which is present at the C-terminus of natural CEA, and also devoid of the additional amino acids which may be attached to the natural CEA through said ethanolamine. Said recombinant CEA glycoproteins s preferably have the amino acid sequence SEQ ID NO: 1. The CEA glycoproteins s of the invention may be used as reagents in an immunoassay for the diagnosis of neoplastic diseases. The invention also relates to a DNA encoding said recombinant CEA glycoprotein, such as the DNA having the nucleotide sequence SEQ ID NO: 2 or a functional equivalent sequence thereof.
    Type: Grant
    Filed: March 23, 1994
    Date of Patent: September 30, 1997
    Assignee: Roche Diagnostic Systems, Inc.
    Inventors: Alexey Terskikh, Andre Pelegrin, Jean-Pierre Mach
  • Patent number: 5670548
    Abstract: A method of pigmenting certain parts and products of poultry, fish and crustacea by including in the feed of the pertinent animal one or more of the carotenoids 2'-dehydroplectaniaxanthin, desmethylspheroidenone, spheroidenone, 1-hydroxy-3,4-didehydro-1,2-dihydro-.psi.,.psi.-caroten-2-one, 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-caroten-6'-one, 1'-hydroxy-3',4'-didehydro-1',2'-dihydro-.beta.,.psi.-carotene-4,2'-dione and 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-carotene-4,6'-dione, poultry, fish and crustacea feeds for pigmenting certains parts and products of these animals, beadlets and premixes for adding to poultry, fish and crustacea feeds, and the carotenoids 1-hydroxy-3,4-didehydro-1,2-dihydro-.psi.,.psi.-caroten-2-one, 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-caroten-6'-one, 1'-hydroxy-3',4'-didehydro-1',2'-dihydro-.beta.,.psi.-carotene-4,2'-dione and 5'-hydroxy-5',6'-dihydro-4'-apo-.beta.-carotene-4,6'-dione.
    Type: Grant
    Filed: October 7, 1996
    Date of Patent: September 23, 1997
    Assignee: Roche Vitamins Inc.
    Inventors: Kurt Bernhard, Jiri Broz, Urs Hengartner, Paul Kreienbuhl, Katharina Schiedt
  • Patent number: 5665581
    Abstract: This invention is directed to naturally virulent fungi which have cells transfected with the coding strand of a mycovirus RNA and which have reduced ability to cause disease in plants, and to compositions and methods of treatment of fungal disease with these fungi.
    Type: Grant
    Filed: June 3, 1994
    Date of Patent: September 9, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Baoshan Chen, Gil Ho Choi, Donald Lee Nuss
  • Patent number: 5648482
    Abstract: A method for the detection of poor metabolizers of drugs using PCR technology is described comprising a) optionally amplifying a gene coding for an enzyme known to be responsible for the metabolization of drugs, thereby separating it from possible closely related pseudogens,b) amplifying different allelic forms of the gene of step a) and c) detecting the product of step b). Primers for amplification of the genes responsible for the debrisoquine or acetylation phenotype are also disclosed.
    Type: Grant
    Filed: March 2, 1994
    Date of Patent: July 15, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Urs Albert Meyer
  • Patent number: 5644024
    Abstract: The present invention is concerned with tetrahydronaphthalene derivatives which are mimics of domains of peptides or proteins which can interact with other proteins or with DNA or RNA through .alpha.-helical conformation, said tetrahydronaphthalene derivatives having the formulae: ##STR1## are valuable aids in the determination of biologically active peptide sequences and are accordingly so-called "research tools". They are, however, also potentially suitable as medicaments.
    Type: Grant
    Filed: August 17, 1994
    Date of Patent: July 1, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christine Abrecht, Klaus Muller, Daniel Obrecht, Arnold Trzeciak
  • Patent number: 5639660
    Abstract: A Polypeptide and DNA Sequence corresponding to the human receptor high affinity receptor for IgE as well as replicable microbial expression vehicles, transformed microorganisms, and cultures of microbial cells which produce this polypeptide.
    Type: Grant
    Filed: February 24, 1988
    Date of Patent: June 17, 1997
    Assignees: Hoffmann-La Roche Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Jean Pierre Kinet, Jarema Peter Kochan
  • Patent number: 5631398
    Abstract: A processes and intermediates useful for the manufacture of the Wittig ester salts are disclosed. The Wittig ester salts are known as important C.sub.5 building blocks for the manufacture of various polyenecarboxylic acid esters in the field of carotenoid chemistry.
    Type: Grant
    Filed: November 16, 1995
    Date of Patent: May 20, 1997
    Assignee: Roche Vitamins Inc.
    Inventors: Bruno Burdet, August R uttimann, Jean-Marie Santer, Theodor Siegfried
  • Patent number: 5600015
    Abstract: There is described a process for the manufacture of isoprene derivatives of the general formula ##STR1## wherein the asymmetric centres can each individually have the (R)- or (S)-configuration, R represents a residue of the formulae ##STR2## R.sup.1 signifies lower alkyl or both R.sup.1 's together signify ethylene or propylene and n stands for the number 0, 1 or 2,in which a compound, which is present in the (E)- or (Z)-form, of the general formula ##STR3## wherein R, n and an optionally present asymmetric centre have the above significance,is asymmetrically hydrogenated with a ruthenium complex of an optically active atropisomeric diphosphine.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: February 4, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Emil A. Broger, Robert K. M uller
  • Patent number: 5595999
    Abstract: Compounds of the formula ##STR1## wherein L, M, R, T and X are set forth in the description, as well as hydrates or solvates thereof, which inhibit thrombin-induced platelet aggregation and clotting of fibrinogen in plasma, are described. The compounds of formula I are prepared by amidination or, depending on whether L is NH or O, by amide formation or esterification.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 21, 1997
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean Ackermann, David Banner, Klaus Gubernator, Paul Hadvary, Kurt Hilpert, Klaus M uller, Ludvik Labler, G erard Schmid, Thomas B. Tschopp, Hans P. Wessel, Beat Wirz
  • Patent number: 5583133
    Abstract: Compounds of the formula ##STR1## wherein L, M, R, T and X are set forth in the description, as well as hydrates or solvates thereof, which inhibit thrombin-induced platelet aggregation and clotting of fibrinogen in plasma, are described. The compounds of formula I are prepared by amidination or, depending on whether L is NH or O, by amide formation or esterification.
    Type: Grant
    Filed: August 4, 1995
    Date of Patent: December 10, 1996
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean Ackermann, David Banner, Klaus Gubernator, Paul Hadvary, Kurt Hilpert, Klaus M uller, Ludvik Labler, G erard Schmid, Thomas B. Tschopp, Hans P. Wessel, Beat Wirz
  • Patent number: 5583248
    Abstract: Compounds of the formula: ##STR1## wherein R.sup.1 is alkoxycarbonyl, aralkoxycarbonyl, alkanoyl, aralkanoyl, heterocyclylcarbonyl or a group of the formula: ##STR2## R.sup.2 is alkyl, cycloalkylalkyl or aralkyl; R.sup.3 is hydrogen and R.sup.4 is hydroxy or R.sup.3 and R.sup.4 together are oxo; R.sup.5 is alkoxycarbonyl or alkylcarbamoyl; R.sup.6 and R.sup.7 together are trimethylene or tetramethylene optionally substituted by alkyl or on adjacent carbon atoms by tetramethylene; R.sup.8 is alkoxycarbonyl, aralkoxycarbonyl, alkanoyl, aroyl, aralkanoyl or heteroeyelylearbonyl; and R.sup.9 is alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, cyanoalkyl, carbamoyl-alkyl, alkylthioalkyl, alkoxyalkyl or alkoxycarbonylalkyl:and pharmaceutically acceptable acid addition salts of those compounds of formula I which are basic, inhibit aspartyl proteases of viral origin and can be used in the form of medicaments for the prophylaxis or treatment of viral infections.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: December 10, 1996
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Joseph A. Martin, Gareth J. Thomas
  • Patent number: 5583222
    Abstract: The compounds of formula I ##STR1## wherein R.sup.1 -R.sup.9, R.sup.15, A, X, Y, Z and n have the meaning given in the specification are active as protein kinase inhibitors and can be used as medicaments, particularly for the treatment of inflammatory skin disorders and alopecia.
    Type: Grant
    Filed: January 4, 1995
    Date of Patent: December 10, 1996
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Pierre Barbier, Isabelle Huber, Fernand Schneider, Josef Stadlwieser, Sven Taylor
  • Patent number: 5578730
    Abstract: A process for the production of a .beta.-aminoalcohol 2-[3(S)-amino-2-hydroxy-4-phenylbutyl]-N-tert.butyl-decahydro-(4aS,8aS)-is oquinoline-3(S)-carboxamide of the formula ##STR1## via the oxazolidinone corresponding to the aminoalcohol 10 which process comprises refluxing a sulphonic acid ester with a carboxamide in the presence of a base and a solvent.
    Type: Grant
    Filed: March 9, 1995
    Date of Patent: November 26, 1996
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Hans Hilpert